CN101926823A - Penetrating agent used for peritoneal dialysate and dialysate thereof - Google Patents
Penetrating agent used for peritoneal dialysate and dialysate thereof Download PDFInfo
- Publication number
- CN101926823A CN101926823A CN2009103120945A CN200910312094A CN101926823A CN 101926823 A CN101926823 A CN 101926823A CN 2009103120945 A CN2009103120945 A CN 2009103120945A CN 200910312094 A CN200910312094 A CN 200910312094A CN 101926823 A CN101926823 A CN 101926823A
- Authority
- CN
- China
- Prior art keywords
- maltose
- dialysis
- peritoneal
- penetrating agent
- dialysis solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention provides a penetrating agent used for a peritoneal dialysate and a dialysate thereof, belonging to the research field of the peritoneal dialysate in peritoneal dialysis treatment of end stage renal disease. The penetrating agent is 2.5-7.5% of maltose aqueous solution, preferably 2.5%, 4.25% or 7.5% of maltose aqueous solution. Per 100 ml of the dialysate prepared by the penetrating agent comprises the following components: 2.5-7.5g of maltose, 535mg of sodium chloride, 448g of sodium lactate, 25.7mg of calcium chloride and 5.08g of magnesium chloride; and preferably, each 100ml of the dialysate comprises 2.5g, 4.25g or 7.5g of maltose. The dialysate prepared by the penetrating agent has good biocompatibility and favorable price, can maintain stable ultrafiltration effect, and generates little side effect in vivo after metabolization.
Description
Technical field
The invention belongs to the research field of peritoneal dialysis solution in the end stagerenaldisease peritoneal dialysis treatment.Relate to a kind of penetrating agent used for peritoneal dialysate and dialysis solution thereof.
Background technology
Peritoneal dialysis is one of a kind of effective treatment end stagerenaldisease method.In peritoneal dialysis, peritoneum is as semipermeable membrane, and there are a large amount of blood vessels and blood capillary in the surface.During dialysis, peritoneal dialysis liquid is managed thoroughly by abdomen and is injected the abdominal cavity, and solute exchanges between peritoneal dialysis liquid and blood vessel, and peritoneal dialysis liquid provides certain osmotic pressure simultaneously, and excess liquid is understood ultrafiltration in the abdominal cavity in the blood vessel, thereby reaches the balance of water, electrolyte and soda acid.And what play a major role in peritoneal dialysis solution is penetrating agent.At present, the penetrating agent of the conventional peritoneal dialysis liquid that uses is mainly glucose, aminoacid, icodextrin etc. in the world, and their characteristics are different.
The dialysis solution that with the glucose is penetrating agent produces many adverse consequencess to human body when forming ultrafiltration.1. glucose can increase with the prolongation of treatment time in Intraabdominal absorption, causes metabolism disorders such as hyperglycemia, hyperinsulinemia, hyperlipemia, hypertension, the increase of body weight quality thus.2. high concentration glucose and glucose degradation product can damage the peritoneal mesothelium cell
[1]High sugar can suppress the propagation of peritoneal mesothelium cell simultaneously, damage peritoneal mesothelium cell, and the stimulation more transforming growth factor-beta 1 of peritoneal mesothelium emiocytosis (TGF-β 1), Connective Tissue Growth Factor (CTGF), Fibrinogen (FN) and plasminogen kinase inhibitive factor (PAI-1), thereby make the extracellular matrix of peritoneal mesothelium cell generate the minimizing that increases, degrades, finally cause the Fibrotic formation of peritoneum
[2,3]3. glucose can cause reducing of osmotic gradient or disappears in Intraabdominal fast Absorption, causes ultrafiltration volume to reduce, even filter occurs surpassing in reverse.4. because glucose and imperfect stability in the peritoneal dialysis liquid, degradable is a 5-hydroxyl first furfural, the latter easily combines with anionic species and forms schiff base, this chemical compound is a kind of early stage glycation product, can change the characteristic of many component of organization, finally can cause peritoneum 26S Proteasome Structure and Function generation irreversible change, cause that the peritoneum ultrafiltration function descends
[4], ultrafiltration depletion finally appears.
Not only possess with the similar toxin of glucose dialysis as the dialysis solution of penetrating agent with aminoacid and to remove and ultrafiltration function, and can effectively improve every nutritive index of renal failure patient in whole latter stage
[5]Can reduce simultaneously contacting of peritoneum and glucose, and its acid-base value higher (pH6.2),, reduce stimulation, and amino acid dialysis do not have the generation of glucose degradation product, further reduced influence the peritoneal mesothelium cell function to peritoneum more near physiological
[6]But following drawbacks limit the application of aminoacid peritoneal dialysis liquid in clinical.1. slight gastrointestinal reaction can take place in the application of amino acid dialysis, as feel sick, vomiting etc., appetite-suppressing simultaneously, and cause metabolic acidosis.2. amino acid dialysis changes the charge property of peritoneal surface, and increases the blood urea nitrogen level, suppresses leukocytic function, increases the weight of the homocysteine mass formed by blood stasis, thereby increase atherosclerotic danger takes place.3. because amino acid whose molecular weight ratio glucose is littler, and it is faster by the speed that peritoneum absorbs, and causes osmotic pressure to descend rapidly, ultrafiltration reduces.
Icodextrin is to be a kind of novel dialytic liquid of penetrating agent with the starch based polysaccharide.Because degraded and absorption are slow in human body, efficient ultrafiltration can keep 8～12h, reaches the peak about 10h, prolongs and stays the abdomen time, and Ultrafiltration does not have obvious minimizing
[7]With respect to traditional dialysis solution, the icodextrin dialysis solution also has other advantages, such as possessing excellent biological compatibility, can reduce the metabolism complication by the absorption that reduces carbohydrate
[8], when increasing ultrafiltration, improve patient's liquid situation, patient's residual renal function there is protective effect etc.
[9]Its weak point is 1. in using the icodextrin peritoneal dialysis solution, because the limitation of measuring method, can produce the false higher of blood glucose value and causes severe hypoglycemia or dead adverse consequences
[10]Because icodextrin accumulating in vivo can allergy mainly show as skin allergy, as erythra, can be slight exfoliative dermatitis when serious
[11]3. because it costs an arm and a leg, greatly limited its use clinically, especially in developing country.
So present situation according to present peritoneal dialysis solution, seek and research and develop novel penetrating agent, develop good biocompatibility, can keep stable ultrafiltration effect, the suitable peritoneal dialysis solution that produces less side effect and price after the metabolism in vivo becomes an important content of present research.
List of references:
[1]Zoltzer.EKlesn，Ra，hidG，etal.Perit?Dia?Int，2000，20(6)：66-61.
[2] Liu Yinghong, Liu Fuyou, Zhang Hao, etc. high sugar is to the propagation of people's peritoneal mesothelium cell and the influence of damage and secrete cytokines. Central South University's journal (medicine) 2006,31 (4): 575-579.
[3]RippiatC，Chen?QM，Remacle?J，et?al?Cell?cycle?regulating?H2O2?inducedpremature?scense?of?human?diploid?fibroblasts?and?regulatory?control?exerted?bythe?papillomavirus?E6?and?E7?proteins.Exp?Geronto，2003，35(6)：733-755.
[4] WitowskiJ, Wi; Niew, kaJ, Ko stings bal, kaK, etal.JAmsoeNePhrol, 2001,12:2434-2441.
[5] Wang Jun, Yu Yusheng, Jia Zhonghui etc. the aminoacid peritoneal dialysis is to the influence of the saturating patient's nutriture of abdomen. and nephropathy is transplanted magazine with dialysis; 2004,13 (4): 330-335.
[6]ChanTM，Leung?JKH，SunYLet?al.Different?effectsof?amino?acid-based?andglucose-based?dialysate?from?peritoneal?dialysis?patients?on?mesothelial?cellultrastructure?and?function[J].Nephrol?Dial?Transplant，2003，18(6)：1086-1094.
[7]Jel?oka?TK，Ers?oy?FF，YavuzM，et?al.What?is?the?optimal?dwell?time?formaximizing?ultrafiltrati?on?with?icodextrin?exchange?in?automated?peritonealdialysis?patients[J]Perit?Dial?I?nt，2006，26(3)：336-340.
[8]Babaz?ono?T，Nakamoto?H，Kasai?K，et?al.Effects?of?icodextrin?onglycemic?and?lipid?profiles?in?diabetic?patients?undergoing?peritonealdialysis[J].Am?J?Nephrol，2007，27(4)：409-415.
[9]Adachi?Y，Nakagawa?Y，Nishi?o?A.Icodextrin?preserves?residual?renalfunction?in?patients?treated?with?automated?peritoneal?dialysis[J].Perit?DialInt，2006，26(3)：405-407.
[10]Slim?S，Griffiths?MJ，Gama?R.I?codextrin-still?a?cause?for?concern?withblood?glucose?monitoring?in?continuous?ambulat?ory?peritoneal?dialysis?patientswith?diabetes[J].Ann?Clin?Biochem，2007，44(Pt2)：196-197.
[11]Lee?SH，Park?HC，Sim?SR，et?al.Severe?cutaneous?hypersensitivity?toicodextrin?in?a?continuous?ambulatory?peritoneal?dialysis?patient[J].JNephrol，2006，19(5)：673-676.
Summary of the invention
The objective of the invention is to exist biocompatibility poor at penetrating agent in present several peritoneal dialysis liquids commonly used, fast in the intraperitoneal infiltration rate, cause metabolism disorder and expensive present situation in vivo, providing a kind of is the penetrating agent used for peritoneal dialysate and the dialysis solution thereof of raw material with maltose (Maltose).In the hope of overcoming above-mentioned shortcoming, improve the usefulness and the biocompatibility of peritoneal dialysis solution.
A kind of penetrating agent used for peritoneal dialysate of the present invention is the maltose solution of 2.5-7.5%.
Described penetrating agent is preferably 2.5%, 4.25% or 7.5% maltose solution.
The dialysis solution of described penetrating agent preparation is the composition that comprises following content in every 100ml dialysis solution: maltose 2.5-7.5g, sodium chloride 535mg, sodium lactate 448mg; Calcium chloride 25.7mg, magnesium chloride 5.08mg.
Comprise maltose 2.5g, 4.25g or 7.5g in preferred every 100ml dialysis solution.
Maltose has following feature as the penetrating agent of peritoneal dialysis solution:
1. maltose is a kind of 2 molecule glucoses by disaccharidase that α-the 1-4 glycosidic bond is formed by connecting.At occurring in nature wide material sources, low price.Its molecular formula C
12H
22O
11, molecular weight 342.296509D, molecular weight is greater than glucose molecule amount 180D, molecular formula C
6H
12O
6, equally greater than aminoacid mean molecule quantity 128D.Less than icodextrin mean molecule quantity 13000～19000D.Maltose structural representation (see figure 1).
2. why to produce Ultrafiltration be to come from the osmotic pressure that penetrating agent produces to peritoneal dialysis solution.The osmotic pressure that the glucose dialysis of variable concentrations produces is between 346-478mOsm/L, the osmotic pressure of aminoacid peritoneal dialysis solution is between 365-396mOsm/L, the osmotic pressure of icodextrin peritoneal dialysis solution is at 282-286mOsm/L, and the osmotic pressure of the maltose peritoneal dialysis liquid of 2.5%-7.5% of the present invention can produce effective ultrafiltration usefulness between 321-432mOsm/L.
3. the non-biocompatible characteristics of traditional glucose dialysis can cause the accumulation of peritoneum angiogenesis and extracellular matrix, cause the structure generation irreversibility of peritoneum to change, thus the infringement of damage peritoneal membrane function.And that the maltose peritoneal dialysis solution contains the glucose degradation product is few, can reduce because high sugar, height oozes and contain the infringement to the peritoneum 26S Proteasome Structure and Function such as glucose degradation product, prolongs the time of peritoneal dialysis.
4. aspect metabolism, traditional glucose dialysis can cause the performance when participating in the cintest of metabolism disorders such as hyperlipemia, hyperglycemia, hyperinsulinemia.Icodextrin dialysis solution metabolite in vivo mainly is Fructus Hordei Germinatus 2 sugar, Fructus Hordei Germinatus 3 sugar, Fructus Hordei Germinatus 4 sugar etc., the further degraded of these metabolites does not need the participation of insulin, so can improve lipodogramme, and show the beneficial effect to the metabolism spectrum, particularly bad patient to glycemic control.The maltose dialysis solution has the metabolic characteristic that is similar to the icodextrin catabolite, so less to metabolic influence.
Advantage and beneficial effect
1. the maltose molecule amount is between glucose and icodextrin, and the osmotic pressure that the maltose peritoneal dialysis solution of same concentrations produces is also between glucose and icodextrin peritoneal dialysis solution.The maltose peritoneal dialysis solution can be kept stable osmotic pressure, and the osmotic pressure of the maltose dialysis solution of 2.5%-7.5% can produce effective ultrafiltration usefulness between 321-432mOsm/L.
2.4 hour rat ultrafiltration experimental result shows, the maltose dialysis solution can produce effective ultrafiltration, wherein the ultrafiltration volume of 2.5% and 4.25% maltose dialysis solution is greater than 2.5%, 4.25% glucose dialysis and 7.5% icodextrin peritoneal dialysis liquid, (P＜0.05), the ultrafiltration volume that 8 hours rat ultrafiltration experimental result shows 2.5% and 4.25% maltose dialysis solution is greater than 2.5%, 4.25% glucose dialysis, (P＜0.05), compare no difference of science of statistics, (P＞0.05) with the icodextrin dialysis solution.
3. observe by experiment in vitro and contain 2.5%, 4.25% maltose culture medium and 2.5%, 4.25% dextrose culture-medium and 7.5% icodextrin culture medium the biocompatibility of people's peritoneal mesothelium cell and the influence of function, the result shows 48 hours and 72 hours, the inhibitory action of above-mentioned culture medium pair cell is least obvious with the maltose group, be better than other two kinds of culture medium, (P＜0.05), 24 hours no obvious significant differences of each group, (P＞0.05).
4. traditional glucose dialysis has high sugar, height oozes and contain non-biocompatible characteristics such as glucose degradation product, can cause the accumulation of peritoneum angiogenesis and extracellular matrix, life-time service can make the structure generation irreversibility of peritoneum change, thus the infringement of damage peritoneal membrane function.And that the maltose peritoneal dialysis solution contains the glucose degradation product is few, can reduce because high sugar, height oozes and contain the infringement to the peritoneum 26S Proteasome Structure and Function such as glucose degradation product, prolongs the time of peritoneal dialysis.Normal rat chronic peritoneal dialysis experimental result shows that the maltose dialysis solution is better than glucose dialysis to peritoneum hypertrophy and Fibrotic influence.
5. aspect metabolism, traditional glucose dialysis can cause the performance when participating in the cintest of metabolism disorders such as hyperlipemia, hyperglycemia, hyperinsulinemia.Icodextrin dialysis solution metabolite in vivo mainly is Fructus Hordei Germinatus 2 sugar, Fructus Hordei Germinatus 3 sugar, Fructus Hordei Germinatus 4 sugar etc., the further degraded of these metabolites does not need the participation of insulin, so can improve lipodogramme, and show the beneficial effect to the metabolism spectrum, particularly bad patient to glycemic control.The maltose dialysis solution has the metabolic characteristic that is similar to the icodextrin catabolite, so less to metabolic influence.
Description of drawings
Fig. 1 is the maltose molecule structural representation;
Fig. 2 adopts high performance liquid chromatography to detect the figure as a result of maltose concentration in normal rat ultrafiltration in the 4 hours experiment;
GLU is a glucose, and MAL is a maltose;
Fig. 3 is the statistical analysis figure of 4 hours ultrafiltration experimental results of normal rat;
From left to right be grouped into 0.9% normal saline, 2.5% glucose dialysis, 4.25% glucose dialysis, 2.5% maltose dialysis solution, 4.25% maltose dialysis solution, 7.5% icodextrin dialysis solution, * represent to compare with 0.9% normal saline group, p＜0.05, # is for to compare with the same concentrations glucose group, p＜0.05;
Fig. 4 is normal rat chronic peritoneal dialysis experiment HE colored graph;
A：0.9％NS；B：2.5％Maltose；C：4.25％Maltose；
Fig. 5 is normal rat chronic peritoneal dialysis experiment Masson colored graph;
A：0.9％NS；B：2.5％Maltose；C：4.25％Maltose；
Fig. 6 is that different dialysis solution are to people's peritoneal mesothelium cell 48 hour cell proliferation experiments;
The 1:2.5% glucose dialysis; The 2:4.25% glucose dialysis; 3:2.5% maltose dialysis solution; 4:4.25% maltose dialysis solution; 5:7.5% icodextrin dialysis solution, * represent and 2.5% glucose dialysis that 4.25% glucose dialysis and 7.5% icodextrin dialysis solution are compared p＜0.05.
Fig. 7 is that different dialysis solution are to people's peritoneal mesothelium cell 72 hour cell proliferation experiments;
The 1:2.5% glucose dialysis; The 2:4.25% glucose dialysis; 3:2.5% maltose dialysis solution; 4:4.25% maltose dialysis solution; 5:7.5% icodextrin dialysis solution; * expression and 2.5% glucose dialysis, 4.25% glucose dialysis and 7.5% icodextrin dialysis solution are compared p＜0.05.
The specific embodiment
Following embodiment is intended to further specify the present invention, rather than restriction the present invention.
1.2.5%, 4.25%, 7.5% maltose dialysis solution prescription is as follows: (content/100ml)
| Maltose | 2.5g/4.25g/7.5g |
| Sodium chloride | 535mg |
| Sodium lactate | 448mg |
| Calcium chloride | 25.7mg |
| Magnesium chloride | 5.08mg |
2. sterilizing methods: maltose dialysis solution glass bottle packaging, sterilizing methods are that 0.1Mpa, 111 ℃, sterilization time are 60min.When temperature is reduced to below 90 ℃, carry out automatic water spray, reduce to 50 ℃ through 60min left and right sides temperature, pressure is zero, opens the disinfection cabinet door.
3. test 1 normal rat ultrafiltration in 4 hours experiment:
Relatively 2.5%, 4.25% maltose dialysis solution and 0.9% normal saline, 2.5% and 4.25% glucose dialysis and 7.5% icodextrin dialysis solution were 4 hours ultrafiltration effect.
Detection method:
Carbamide in blood plasma and the dialysis solution, albumen and concentration of glucose are measured with Luo Shi modular DPP automatic biochemistry analyzer.
2) osmotic pressure detects: adopt the freezing point osmotic pressure detection method, use instrument to be the full-automatic freezing point osmotic pressure detector of FM8P.
3) maltose content detection method: high performance liquid chromatography is adopted in the detection for maltose concentration, use the Agilent1100 chromatograph, the BioBasic AX of Thermo company, 5um, the 150*4.6mm test column, mobile phase is the warm and fine water of second, ratio is 75: 25, flow velocity is 1ml/min, and column temperature is 25 ℃, uses two kinds of methods of fluorescence and ultraviolet to detect.See Fig. 2, first peak is a glucose, and second peak is maltose.
Experimental result:
Wherein the ultrafiltration volume of 2.5% maltose dialysis solution is greater than the ultrafiltration volume of 2.5% glucose dialysis, and difference has statistical significance (P＜0.05); The ultrafiltration volume of 4.25% maltose dialysis solution is greater than 4.25% glucose dialysis and 7.5% icodextrin dialysis solution, and difference has statistical significance (P＜0.05), sees Fig. 3.
4. test 2 normal rat chronic peritoneal dialysises experiments (time is about 1 month):
Relatively 2.5%, 4.25% maltose dialysis solution and 0.9% normal saline, 2.5% and 4.25% glucose dialysis and 7.5% icodextrin dialysis solution are to the influence of normal rat peritoneum 26S Proteasome Structure and Function.
Detection method:
Peritoneum thickness detects: detect HE dyeing and the painted peritoneum thickness of Masson respectively.Three experimenters through training by different at microscopically, select five different points, measure the thickness from the peritoneal mesothelium cell to Musclar layer, take the mean as the thickness of the peritoneum of surveying.Use (Olympus BX-40, Melville, NY) optical microscope.
Experimental result:
1) normal rat chronic peritoneal dialysis experiment ultrafiltration result is with experiment 1.
2) HE dyeing (Fig. 4) and Masson dyeing (Fig. 5) result demonstration is compared with 0.9% normal saline, and 2.5%, 4.25% maltose group does not have obvious statistical significance (P＞0.05) to the influence of peritoneum thickness.
Relatively 2.5%, 4.25% maltose dialysis solution and 0.9% normal saline, 2.5% and 4.25% glucose dialysis and 7.5% icodextrin dialysis solution are to the influence of people's peritoneal mesothelium cell growth.
Experiment material:
1) reagent and consumptive material
| People's peritoneal mesothelium cell strain | Central South University genetic experiment chamber is frozen |
| Hyclone | Hangzhou Ilex purpurea Hassk.[I.chinensis Sims biotech company |
| Pancreatin | Sigma company (4 ℃ of storages) |
| The DMEM culture medium | Gibco |
| Tissue Culture Plate | Corning company |
| Tissue Culture Flask | Corning company |
| MTT | Solarbio |
| The LDH testing cassete | Bio-engineering research institute is built up in Nanjing |
| Trypan blue | The refined two HC laboratorys in Hunan |
| The disposable centrifuge tube of 15ml | Corning |
| The disposable centrifuge tube of 50ml | Corning |
| 0.2ml PCR pipe | Axygen |
| 1.5ml eppendorf pipe | Axygen |
| The antiseptic rubber latex examination gloves | Peace medical device company limited wafts in Changsha |
| Disposable PE glove | Peace medical device company limited wafts in Changsha |
2) experimental facilities:
3) 2.5%, 4.25% maltose dialysis solution is prepared with said method, and 0.9% normal saline provides for refined two hospital preparation chambers, Hunan, and 2.5%, 4.25% glucose dialysis and 7.5% icodextrin dialysis solution are so kind as to give by hundred special companies.
Experimental procedure:
1) cultivates and go down to posterity
Normal person's peritoneal mesothelium cell (HPMC) is all cultivated with the F12 culture medium, at 37 ℃, 5%CO
2Growing to 80%～90% under the condition goes down to posterity when converging.Inhale and remove the culture medium of cultivating in the vessel, with PBS washed cell 1 time, discard PBS, add an amount of 0.1% pancreatin solution digestion according to culture area, place 3～5min for 37 ℃, and under inverted microscope, observe, stop digestion by the time most cell roundings promptly add culture medium, with discrete agglomerating cell, the HPMC cell goes down to posterity in 1: 3～1: 4 ratio several times in piping and druming.Cell after going down to posterity is in 37 ℃, 5%CO
2Change liquid once after cultivating 24h, to remove the dead cell in digestion back, later every 2d changes liquid once totally totally.
2) cell intervention
The HPMC cell is cultivated, gone down to posterity.Treat to digest when cell grows to 80% fusion, add culture medium and stop the back, regulate cell concentration to 1-5 * 10 with the capable cell numeration of blood cell counting plate
4After, be inoculated into 96 well culture plates.Treat that cell grows to about 70%～80% when merging, spend the night, intervene test again with serum-free DMEM culture medium culturing.
Be divided into 0.9% normal saline group, 2.5%, 4.25% glucose dialysis group, 2.5%, 4.25% maltose dialysis solution group and 7.5% icodextrin dialysis solution group, each group are established 3 multiple holes, intervene respectively 24,48,72 hours.Every hole adds 5mg/ml MTT solution 20 μ l, 37 ℃, 5%CO
2Incubator continued to hatch 4 hours, stopped cultivating, and careful the suction abandoned culture supernatant in each hole; Every hole adds 150 μ l DMSO, vibration 10min, and Shi Jia Za fully dissolves.
Detection method:
1) on enzyme-linked immunosorbent assay instrument, uses 570nm wavelength colorimetric, measure each hole A value, return to zero with blank well.
Statistical analysis:
Numerical value is represented with mean ± standard deviation, adopts SPSS17.0 software, and relatively with one factor analysis of variance or T check, (P＜0.05) has statistical significance for difference between group.
Experimental result:
24 hour cell proliferation experiment results show and respectively organize no significant difference (P＞0.05), 48 and 72 hour cell proliferation experiment results show maltose dialysis solution group to the influence of the propagation of people's peritoneal mesothelium cell less than other each groups, difference has statistical significance (* P＜0.05).(1 group of 2.5% glucose dialysis, 2 group of 4.25% glucose dialysis, 3 group of 2.5% maltose dialysis solution, 4 group of 4.25% maltose dialysis solution, 5 group of 7.5% icodextrin dialysis solution.)
See Fig. 6 and Fig. 7.
Claims (8)
1. a penetrating agent used for peritoneal dialysate is characterized in that, described penetrating agent is the maltose solution of 2.5-7.5%.
2. penetrating agent according to claim 1 is characterized in that, described penetrating agent is 2.5% maltose solution.
3. penetrating agent according to claim 1 is characterized in that, described penetrating agent is 4.25% maltose solution.
4. penetrating agent according to claim 1 is characterized in that, described penetrating agent is 7.5% maltose solution.
5. the dialysis solution of the described penetrating agent preparation of claim 1 is characterized in that, comprises the composition of following content in every 100ml dialysis solution: maltose 2.5-7.5g, sodium chloride 535mg, sodium lactate 448mg; Calcium chloride 25.7mg, magnesium chloride 5.08mg.
6. the dialysis solution of penetrating agent preparation according to claim 5 is characterized in that, comprises maltose 2.5g in every 100ml dialysis solution.
7. the dialysis solution of penetrating agent preparation according to claim 5 is characterized in that, comprises maltose 4.25g in every 100ml dialysis solution.
8. the dialysis solution of penetrating agent preparation according to claim 5 is characterized in that, comprises maltose 7.5g in every 100ml dialysis solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103120945A CN101926823A (en) | 2009-12-23 | 2009-12-23 | Penetrating agent used for peritoneal dialysate and dialysate thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103120945A CN101926823A (en) | 2009-12-23 | 2009-12-23 | Penetrating agent used for peritoneal dialysate and dialysate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101926823A true CN101926823A (en) | 2010-12-29 |
Family
ID=43366427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009103120945A Pending CN101926823A (en) | 2009-12-23 | 2009-12-23 | Penetrating agent used for peritoneal dialysate and dialysate thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101926823A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988414A (en) * | 2012-12-13 | 2013-03-27 | 天津金耀集团有限公司 | Peritoneal dialysis fluid (lactate) (low-calcium) composition |
| CN107854482A (en) * | 2017-10-27 | 2018-03-30 | 宋宏婷 | A kind of high peritoneal dialysis solution of dehydration rate |
| CN109589466A (en) * | 2017-10-03 | 2019-04-09 | 美敦力公司 | Peritoneal dialysis solution humidity control system |
| CN110269867A (en) * | 2018-03-14 | 2019-09-24 | 必康生技（香港）有限公司 | Composition for biofluid purification |
-
2009
- 2009-12-23 CN CN2009103120945A patent/CN101926823A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988414A (en) * | 2012-12-13 | 2013-03-27 | 天津金耀集团有限公司 | Peritoneal dialysis fluid (lactate) (low-calcium) composition |
| CN102988414B (en) * | 2012-12-13 | 2014-05-28 | 天津金耀集团有限公司 | Peritoneal dialysis fluid (lactate) (low-calcium) composition |
| CN109589466A (en) * | 2017-10-03 | 2019-04-09 | 美敦力公司 | Peritoneal dialysis solution humidity control system |
| CN107854482A (en) * | 2017-10-27 | 2018-03-30 | 宋宏婷 | A kind of high peritoneal dialysis solution of dehydration rate |
| CN110269867A (en) * | 2018-03-14 | 2019-09-24 | 必康生技（香港）有限公司 | Composition for biofluid purification |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103655652B (en) | A kind of concocting method of low dry property Radix Ginseng | |
| JP2011140519A (en) | Method and composition for detection of microbial contaminant in peritoneal dialysis solution | |
| Bonomini et al. | L-carnitine is an osmotic agent suitable for peritoneal dialysis | |
| Ku et al. | Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa | |
| CN101926823A (en) | Penetrating agent used for peritoneal dialysate and dialysate thereof | |
| Bonomini et al. | How to improve the biocompatibility of peritoneal dialysis solutions (without jeopardizing the patient’s health) | |
| Vigil et al. | Adverse effects of high doses of intravenous alpha lipoic acid on liver mitochondria | |
| Çomu et al. | Effect of picroside II on erythrocyte deformability and lipid peroxidation in rats subjected to hind limb ischemia reperfusion injury | |
| CN102293780A (en) | Sodium acetate Ringer's injection and its preparation method | |
| CN101450075B (en) | Hydroxyethyl starch 130/0.4 sodium chloride injection and preparation method and use thereof | |
| Sheng et al. | Chinese medicinal formula Fufang Xueshuantong capsule could inhibit the activity of angiotensin converting enzyme | |
| Ohashi et al. | Microdialysis detection of lactate in subcutaneous tissue as a reliable indicator of tissue metabolic disorders in an animal sepsis model | |
| CN101168008B (en) | Medicinal composition with tumor inhibition function and preparation method and application thereof | |
| CN104288139B (en) | Mango aglycone derivative is prevented and treated the application in diabetes and complication medicine thereof in preparation | |
| CN101822690B (en) | Composition of dextran 40 and sodium lactate Ringer' solution and preparation method | |
| of the Guideline et al. | Chinese Clinical Practice Guideline for the Management of “CKD-PeriDialysis”-the Periods Prior to and in the Early-Stage of Initial Dialysis | |
| CN106831904A (en) | A kind of compound and preparation method thereof, preparation and application | |
| CN102204949B (en) | Method for preparing dalbergia odorifera seed extract and dalbergia odorifera seed extract | |
| CN102000106B (en) | Medicinal composition for preventing and treating vascular injury caused by organic phosphorous pesticide and preparation method thereof | |
| CN109045143A (en) | A kind of manufacturing method of Chinese medicine perineum ice compress pad | |
| CN1197623C (en) | Sparagin injection using xylitol as isosmotic adjusting agent | |
| CN103539854A (en) | Extracorporeal dynamic circulation method for preparing advanced glycation end products | |
| CN101559047A (en) | Function of xylitol erythritol in wound irrigation | |
| CN103432183A (en) | Polyphenol extract in callistephus chinensis and preparation method as well as application thereof | |
| CN101167739A (en) | Compound fructose electrolyte injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20101229 |